Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials - Yang, JC-H; Wu, Y-L; Schuler, M (The Lancet Oncology, 2015)
et al.